Several nuclear imaging and cerebrospinal fluid (CSF) biomarkers are under investigation, aimed at facilitating the differential diagnosis of dementias.
Objective:
To quantitatively synthesize data on test performance in differentiating dementia with Lewy bodies (DLB) from other dementias.
Methods:
We searched PubMed (January 2000– March 2015) for English-language publications that assessed a selected set of five imaging and three CSF biomarkers for this purpose. We meta-analyzed measures of agreement between biomarker results and clinical diagnosis.
Results:
Forty-five publications were eligible. The majority of evidence was based on studies that enrolled representative disease populations. For differentiating between DLB and Alzheimer’s disease (AD) or other dementias, metaiodobenzylguanidine scintigraphy and dopamine transporter (DAT) single photon emission computed tomography (SPECT) showed, respectively, excellent (summary kappa = 0.85; 95% confidence interval [95% CI], 0.74–0.96) and good (summary kappa = 0.71; 95% CI, 0.43–0.99) agreement. Metaiodobenzylguanidine scintigraphy appeared superior to fluorodeoxyglucose– positron emission tomography (summary kappa = 0.53; 95% CI, 0.36–0.69) and cerebral blood flow SPECT (summary kappa = 0.40; 95% CI, 0.33–0.47). For differentiating DLB from AD, CSF t-tau levels (summary kappa = 0.68; 95% CI, 0.55–0.82) performed comparably to metaiodobenzylguanidine scintigraphy and DAT SPECT. Sparse direct comparative evidence failed to corroborate these indirect comparisons.
Conclusion:
Metaiodobenzylguanidine scintigraphy and DAT SPECT are highly concordant with clinical diagnosis in differentiating DLB from other dementias. However, given the limitations in the study design, the applicability of these results to real-world differential diagnosis remains unclear. Prospective studies targeting patients with atypical presentations that adopt gold standard tests would reliably estimate the true test performance of these promising biomarkers.
Vann JonesSA, O’BrienJT (2014) The prevalence and incidence of dementia with Lewy bodies: A systematic review of population and clinical studies. Psychol Med44, 673–683.
2.
McKeithIG, GalaskoD, KosakaK, PerryEK, DicksonDW, HansenLA, SalmonDP, LoweJ, MirraSS, ByrneEJ, LennoxG, QuinnNP, EdwardsonJA, IncePG, BergeronC, BurnsA, MillerBL, LovestoneS, CollertonD, JansenEN, BallardC, de VosRA, WilcockGK, JellingerKA, PerryRH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology47, 1113–1124.
3.
McKeithIG (2006) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop. J Alzheimers Dis9, 417–423.
4.
ZweigYR, GalvinJE (2014) Lewy body dementia: The impact on patients and caregivers. Alzheimers Res Ther6, 21.
OssenkoppeleR, JansenWJ, RabinoviciGD, KnolDL, van der FlierWM, van BerckelBN, ScheltensP, VisserPJ, VerfaillieSC, ZwanMD, AdriaanseSM, LammertsmaAA, BarkhofF, JagustWJ, MillerBL, RosenHJ, LandauSM, VillemagneVL, RoweCC, LeeDY, NaDL, SeoSW, SarazinM, RoeCM, SabriO, BarthelH, KoglinN, HodgesJ, LeytonCE, VandenbergheR, van LaereK, DrzezgaA, ForsterS, GrimmerT, Sanchez-JuanP, CarrilJM, MokV, CamusV, KlunkWE, CohenAD, MeyerPT, HellwigS, NewbergA, FrederiksenKS, FleisherAS, MintunMA, WolkDA, NordbergA, RinneJO, ChetelatG, LleoA, BlesaR, ForteaJ, MadsenK, RodrigueKM, BrooksDJ (2015) Prevalence of amyloid PET positivity in dementia syndromes: A meta-analysis. JAMA313, 1939–1949.
7.
LimX, YeoJM, GreenA, PalS (2013) The diagnostic utility of cerebrospinal fluid alpha-synuclein analysis in dementia with Lewy bodies - a systematic review and meta-analysis. Parkinsonism Relat Disord19, 851–858.
8.
MayoMC, BordelonY (2014) Dementia with Lewy bodies. Semin Neurol34, 182–188.
9.
DavisonCM, O’BrienJT (2014) A comparison of FDG-PET and blood flow SPECT in the diagnosis of neurodegenerative dementias: A systematic review. Int J Geriatr Psychiatry29, 551–561.
10.
McCleeryJ, MorganS, BradleyKM, Noel-StorrAH, AnsorgeO, HydeC (2015) Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies. Cochrane Database Syst Rev1, CD010633.
11.
SinhaN, FirbankM, O’BrienJT (2012) Biomarkers in dementia with Lewy bodies: A review. Int J Geriatr Psychiatry27, 443–453.
12.
van HartenAC, KesterMI, VisserPJ, BlankensteinMA, PijnenburgYA, van der FlierWM, ScheltensP (2011) Tau and p-tau as CSF biomarkers in dementia: A meta-analysis. Clin Chem Lab Med49, 353–366.
13.
PapathanasiouND, BoutsiadisA, DicksonJ, BomanjiJB (2012) Diagnostic accuracy of (1)(2)(3)I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: A meta-analysis of published studies. Parkinsonism Relat Disord18, 225–229.
TregliaG, CasonE (2012) Diagnostic performance of myocardial innervation imaging using MIBG scintigraphy in differential diagnosis between dementia with lewy bodies and other dementias: A systematic review and a meta-analysis. J Neuroimaging22, 111–117.
16.
YeoJM, LimX, KhanZ, PalS (2013) Systematic review of the diagnostic utility of SPECT imaging in dementia. Eur Arch Psychiatry Clin Neurosci263, 539–552.
17.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology34, 939–944.
18.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
19.
DuboisB, FeldmanHH, JacovaC, DekoskyST, Barberger-GateauP, CummingsJ, DelacourteA, GalaskoD, GauthierS, JichaG, MeguroK, O’BrienJ, PasquierF, RobertP, RossorM, SallowayS, SternY, VisserPJ, ScheltensP (2007) Research criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol6, 734–746.
WhitingPF, RutjesAW, WestwoodME, MallettS, DeeksJJ, ReitsmaJB, LeeflangMM, SterneJA, BossuytPM (2011) QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med155, 529–536.
22.
TrikalinosTA, BalionCM (2012) Chapter 9: Options for summarizing medical test performance in the absence of a “gold standard”. J Gen Intern Med27(Suppl 1), S67–S75.
23.
PhillipsB, StewartLA, SuttonAJ (2010) ‘Cross hairs’ plots for diagnostic meta-analysis. Res Synth Methods1, 308–315.
24.
ReitsmaJB, GlasAS, RutjesAW, ScholtenRJ, BossuytPM, ZwindermanAH (2005) Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol58, 982–990.
25.
HarbordRM, DeeksJJ, EggerM, WhitingP, SterneJA (2007) A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics8, 239–251.
26.
DahabrehIJ, TrikalinosTA, LauJ, SchmidC (2012) An empirical assessment of bivariate methods for meta-analysis of test accuracy [Internet]. Agency for Healthcare Research and Quality (US), Rockville, MD.
27.
RutterCM, GatsonisCA (2001) A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med20, 2865–2884.
28.
SunS (2011) Meta-analysis of Cohen’s kappa. Health Serv Outcomes Res Methodol11, 145–163.
29.
AltmanDG (2006) Practical Statistics for Medical Research, Chapman & Hall/CRC.
30.
LandisJR, KochGG (1977) The measurement of observer agreement for categorical data. Biometrics33, 159–174.
31.
MacaskillP, GatsonisC, DeeksJ, HarbordR, TakwoingiY (2010) Chapter 10: Analysing and presenting results. In Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0, DeeksJJ, BossuytPM, BossuytC, eds. The Cochrane Collaboration. Available from http://srdta.cochrane.org/.
32.
TakwoingiY, LeeflangMMG, DeeksJJ (2013) Empirical evidence of the importance of comparative studies of diagnostic test accuracy. Ann Intern Med158, 544–554.
33.
HigginsJP, ThompsonSG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med21, 1539–1558.
SterneJA, SuttonAJ, IoannidisJP, TerrinN, JonesDR, LauJ, CarpenterJ, RuckerG, HarbordRM, SchmidCH, TetzlaffJ, DeeksJJ, PetersJ, MacaskillP, SchwarzerG, DuvalS, AltmanDG, MoherD, HigginsJP (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.d. BMJ343, 4002.
36.
BrooksSP, GelmanA (1998) General methods for monitoring convergence of iterative simulations. J Comput Graph Stat7, 434–455.
37.
ThompsonJ (2014) Bayesian Analysis with Stata, Stata Press.
38.
HiguchiM, TashiroM, AraiH, OkamuraN, HaraS, HiguchiS, ItohM, ShinRW, TrojanowskiJQ, SasakiH (2000) Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol162, 247–256.
39.
MinoshimaS, FosterNL, SimaAAF, FreyKA, AlbinRL, KuhlDE (2001) Alzheimer’s disease versus dementia with Lewy bodies: Cerebral metabolic distinction with autopsy confirmation. Ann Neurol50, 358–365.
40.
KoeppeRA, GilmanS, JoshiA, LiuS, LittleR, JunckL, HeumannM, FreyKA, AlbinRL (2005) 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. J Nucl Med46, 936–944.
41.
KonoAK, IshiiK, SofueK, MiyamotoN, SakamotoS, MoriE (2007) Fully automatic differential diagnosis system for dementia with Lewy bodies and Alzheimer’s disease using FDG-PET and 3D-SSP. Eur J Nucl Med Mol Imaging34, 1490–1497.
42.
MosconiL, TsuiWH, HerholzK, PupiA, DrzezgaA, LucignaniG, ReimanEM, HolthoffV, KalbeE, SorbiS, Diehl-SchmidJ, PerneczkyR, ClericiF, CaselliR, Beuthien-BaumannB, KurzA, MinoshimaS, deLeon MJ (2008) Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med49, 390–398.
43.
LimSM, KatsifisA, VillemagneVL, BestR, JonesG, SalingM, BradshawJ, MeroryJ, WoodwardM, HopwoodM, RoweCC (2009) The 18F-FDG PET cingulate island sign and comStata Presson to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med50, 1638–1645.
44.
OssenkoppeleR, PrinsND, PijnenburgYA, LemstraAW, van der FlierWM, AdriaanseSF, WindhorstAD, HandelsRL, WolfsCA, AaltenP, VerheyFR, VerbeekMM, van BuchemMA, HoekstraOS, LammertsmaAA, ScheltensP, van BerckelBN (2013) Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer’s Dement9, 414–421.
45.
O’BrienJT, FirbankMJ, DavisonC, BarnettN, BamfordC, DonaldsonC, OlsenK, HerholzK, WilliamsD, LloydJ (2014) 18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias. J Nucl Med55, 1959–1965.
46.
SpehlTS, HellwigS, AmtageF, WeillerC, BormannT, WeberWA, HullM, MeyerPT, FringsL (2015) Syndrome-specific patterns of regional cerebral glucose metabolism in posterior cortical atrophy in comparison to dementia with Lewy bodies and Alzheimer’s disease–a [F-18]-FDG pet study. J Neuroimaging25, 281–288.
47.
WatanabeH, IedaT, KatayamaT, TakedaA, AibaI, DoyuM, HirayamaM, SobueG (2001) Cardiac (123)I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: Comparison with Alzheimer’s disease.. J Neurol Neurosurg Psychiatry70, 781–783.
48.
OideT, TokudaT, MomoseM, OguchiK, NakamuraA, OharaS, IkedaS (2003) Usefulness of [123I]metaiodobenzylguanidine ([123I]MIBG) myocardial scintigraphy in differentiating between Alzheimer’s disease and dementia with Lewy bodies. Intern Med42, 686–690.
49.
JindahraP, VejjajivaA, WitoonpanichR, SirisriroR, SritaraC, PulkesT (2004) Differentiation of dementia with Lewy bodies, Alzheimer’s disease and vascular dementia by cardiac 131I-meta-iodobenzylguanidine (MIBG) uptake (preliminary report). J Med Assoc Thai87, 1176–1181.
50.
HanyuH, ShimizuS, HiraoK, KanetakaH, IwamotoT, ChikamoriT, UsuiY, YamashinaA, KoizumiK, AbeK (2006) Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer’s disease. Eur J Nucl Med Mol Imaging33, 248–253.
51.
HanyuH, ShimizuS, HiraoK, SakuraiH, IwamotoT, ChikamoriT, HidaS, YamashinaA, KoizumiK, AbeK (2006) The role of 123I-metaiodobenzylguanidine myocardial scintigraphy in the diagnosis of Lewy body disease in patients with dementia in a memory clinic. Dement Geriatr Cogn Disord22, 379–384.
52.
YoshitaM, TakiJ, YokoyamaK, Noguchi-ShinoharaM, MatsumotoY, NakajimaK, YamadaM (2006) Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology66, 1850–1854.
53.
Wada-IsoeK, KitayamaM, NakasoK, NakashimaK (2007) Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study. J Neurol Sci260, 33–37.
54.
EstorchM, CamachoV, ParedesP, RiveraE, Rodriguez-RevueltoA, FlotatsA, KulisevskyJ, CarrioI (2008) Cardiac (123)I-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life. Eur J Nucl Med Mol Imaging35, 1636–1641.
55.
Noguchi-ShinoharaM, TokudaT, YoshitaM, KasaiT, OnoK, NakagawaM, El-AgnafOM, YamadaM (2009) CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer’s disease. Brain Res1251, 1–6.
56.
SakamotoF, ShiraishiS, YoshidaM, TomiguchiS, HiraiT, NamimotoT, HashimotoM, IkedaM, UetaniH, YamashitaY (2014) Diagnosis of dementia with Lewy bodies: Diagnostic performance of combined (1)(2)(3)I-IMP brain perfusion SPECT and (1)(2)(3)I-MIBG myocardial scintigraphy. Ann Nucl Med28, 203–211.
57.
SlaetsS, Van AckerF, VersijptJ, HauthL, GoemanJ, MartinJJ, De DeynPP, EngelborghsS (2015) Diagnostic value of MIBG cardiac scintigraphy for differential dementia diagnosis. Int J Geriatr Psychiatry30, 864–869.
58.
InuiY, ToyamaH, ManabeY, SaraiM, IwataN (2014) Comparison of (123)I-MIBG myocardial scintigraphy, brain perfusion SPECT, and voxel-based MRI morphometry for distinguishing between dementia with Lewy bodies and Alzheimer’s disease. Ann Nucl Med28, 796–804.
59.
TregliaG, CasonE, CortelliP, GabelliniA, LiguoriR, BagnatoA, GiordanoA, FagioliG (2014) Iodine-123 metaiodobenzylguanidine scintigraphy and iodine-123 ioflupane single photon emission computed tomography in Lewy body diseases: Complementary or alternative techniques?J Neuroimaging24, 149–154.
WalkerZ, JarosE, WalkerRW, LeeL, CostaDC, LivingstonG, IncePG, PerryR, McKeithI, KatonaCL (2007) Dementia with Lewy bodies: A comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry78, 1176–1181.
62.
CollobySJ, FirbankMJ, PakrasiS, LloydJJ, DriverI, McKeithIG, WilliamsED, O’BrienJT (2008) A comparison of 99mTc-exametazime and 123I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer’s disease and dementia with Lewy bodies. Int Psychogeriatr20, 1124–1140.
63.
O’BrienJT, McKeithIG, WalkerZ, TatschK, BooijJ, DarcourtJ, MarquardtM, ReiningerC (2009) Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br J Psychiatry194, 34–39.
64.
KempPM, ClydeK, HolmesC (2011) Impact of 123I-FP-CIT (DaTSCAN) SPECT on the diagnosis and management of patients with dementia with Lewy bodies: A retrospective study. Nucl Med Commun32, 298–302.
65.
LobotesisK, FenwickJD, PhippsA, RymanA, SwannA, BallardC, McKeithIG, O’BrienJT (2001) Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology56, 643–649.
66.
PasquierJ, MichelBF, Brenot-RossiI, Hassan-SebbagN, SauvanR, GastautJL (2002) Value of (99m)Tc-ECD SPET for the diagnosis of dementia with Lewy bodies. Eur J Nucl Med Mol Imaging29, 1342–1348.
67.
HanyuH, ShimizuS, HiraoK, KanetakaH, SakuraiH, IwamotoT, KoizumiK, AbeK (2006) Differentiation of dementia with Lewy bodies from Alzheimer’s disease using Mini-Mental State Examination and brain perfusion SPECT. J Neurol Sci250, 97–102.
68.
IshiiK, KandaT, UemuraT, MiyamotoN, YoshikawaT, ShimadaK, OhkawaS, MinoshimaS (2009) Computer-assisted diagnostic system for neurodegenerative dementia using brain SPECT and 3D-SSP. Eur J Nucl Med Mol Imaging36, 831–840.
69.
CollobySJ, TaylorJP, FirbankMJ, McKeithIG, WilliamsED, O’BrienJT (2010) Covariance 99mTc-exametazime SPECT patterns in Alzheimer’s disease and dementia with Lewy bodies: Utility in differential diagnosis. J Geriatr Psychiatry Neurol23, 54–62.
70.
BuergerK, ZinkowskiR, TeipelSJ, TapiolaT, AraiH, BlennowK, AndreasenN, Hofmann-KieferK, DeBernardisJ, KerkmanD, McCullochC, KohnkenR, PadbergF, PirttilaT, SchapiroMB, RapoportSI, MollerHJ, DaviesP, HampelH (2002) Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol59, 1267–1272.
71.
Gomez-TortosaE, GonzaloI, FanjulS, SainzMJ, CantareroS, CemillanC, YebenesJG, delSer T (2003) Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Arch Neurol60, 1218–1222.
72.
HampelH, BuergerK, ZinkowskiR, TeipelSJ, GoernitzA, AndreasenN, SjoegrenM, DeBernardisJ, KerkmanD, IshiguroK, OhnoH, VanmechelenE, VandersticheleH, McCullochC, MollerHJ, DaviesP, BlennowK (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: A comparative cerebrospinal fluid study. Arch Gen Psychiatry61, 95–102.
73.
ParaskevasGP, KapakiE, LiappasI, TheotokaI, MamaliI, ZournasC, LykourasL (2005) The diagnostic value of cerebrospinal fluid tau protein in dementing and nondementing neuropsychiatric disorders. J Geriatr Psychiatry Neurol18, 163–173.
74.
BiblM, MollenhauerB, EsselmannH, LewczukP, KlafkiHW, SparbierK, SmirnovA, CepekL, TrenkwalderC, RutherE, KornhuberJ, OttoM, WiltfangJ (2006) CSF amyloid-beta-peptides in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia. Brain129, 1177–1187.
75.
deJong D, JansenRW, PijnenburgYA, van GeelWJ, BormGF, KremerHP, VerbeekMM (2007) CSF neurofilament proteins in the differential diagnosis of dementia. J Neurol Neurosurg Psychiatry78, 936–938.
76.
NielsenHM, MinthonL, LondosE, BlennowK, MirandaE, PerezJ, CrowtherDC, LomasDA, JanciauskieneSM (2007) Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology69, 1569–1579.
77.
KasugaK, TokutakeT, IshikawaA, UchiyamaT, TokudaT, OnoderaO, NishizawaM, IkeuchiT (2010) Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer’s disease. J Neurol Neurosurg Psychiatry81, 608–610.
78.
SpiesPE, SlatsD, SjogrenJM, KremerBP, VerheyFR, RikkertMG, VerbeekMM (2010) The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer’s disease from non-Alzheimer’s dementia. Curr Alzheimer Res7, 470–476.
79.
LuoX, HouL, ShiH, ZhongX, ZhangY, ZhengD, TanY, HuG, MuN, ChanJ, ChenX, FangY, WuF, HeH, NingY (2013) CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer’s disease and dementia with Lewy bodies. J Neurochem127, 681–690.
80.
NutuM, ZetterbergH, LondosE, MinthonL, NaggaK, BlennowK, HanssonO, OhrfeltA (2013) Evaluation of the cerebrospinal fluid amyloid-beta1-42/amyloid-beta1-40 ratio measured by alpha-LISA to distinguish Alzheimer’s disease from other dementia disorders. Dement Geriatr Cogn Disord36, 99–110.
81.
EwersM, MattssonN, MinthonL, MolinuevoJL, AntonellA, PoppJ, JessenF, HerukkaSK, SoininenH, MaetzlerW, LeyheT, BurgerK, TaniguchiM, UrakamiK, ListaS, DuboisB, BlennowK, HampelH (2015) CSF biomarkers for the differential diagnosis of Alzheimer’s disease. A large-scale international multicenter study. Alzheimers Dement11, 1306–1315.
82.
StruyfsH, Van BroeckB, TimmersM, FransenE, SleegersK, Van BroeckhovenC, De DeynPP, StrefferJR, MerckenM, EngelborghsS (2015) Diagnostic accuracy of cerebrospinal fluid amyloid-beta isoforms for early and differential dementia diagnosis. J Alzheimers Dis45, 813–822.
83.
BiblM, MollenhauerB, EsselmannH, LewczukP, TrenkwalderC, BrechlinP, RutherE, KornhuberJ, OttoM, WiltfangJ (2006) CSF diagnosis of Alzheimer’s disease and dementia with Lewy bodies. J Neural Transm113, 1771–1778.
84.
RutjesAW, ReitsmaJB, VandenbrouckeJP, GlasAS, BossuytPM (2005) Case-control and two-gate designs in diagnostic accuracy studies. Clin Chem51, 1335–1341.
85.
ParkkinenL, PirttilaT, AlafuzoffI (2008) Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol115, 399–407.
86.
FrigerioR, FujishiroH, AhnTB, JosephsKA, MaraganoreDM, DelleDonneA, ParisiJE, KlosKJ, BoeveBF, DicksonDW, AhlskogJE (2011) Incidental Lewy body disease: Do some cases represent a preclinical stage of dementia with Lewy bodies?Neurobiol Aging32, 857–863.
87.
KoopmanK, Le BastardN, MartinJJ, NagelsG, De DeynPP, EngelborghsS (2009) Improved discrimination of autopsy-confirmed Alzheimer’s disease (AD) from non-AD dementias using CSF P-tau(181P). Neurochem Int55, 214–218.
88.
SlaetsS, Le BastardN, TheunsJ, SleegersK, VerstraetenA, De LeenheirE, LuyckxJ, MartinJJ, Van BroeckhovenC, EngelborghsS (2013) Amyloid pathology influences abeta1-42 cerebrospinal fluid levels in dementia with lewy bodies. J Alzheimers Dis35, 137–146.
89.
NelsonPT, JichaGA, KryscioRJ, AbnerEL, SchmittFA, CooperG, XuLO, SmithCD, MarkesberyWR (2010) Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol257, 359–366.
DendukuriN, SchillerI, JosephL, PaiM (2012) Bayesian meta-analysis of the accuracy of a test for tuberculous pleuritis in the absence of a gold standard reference. Biometrics68, 1285–1293.
92.
MentenJ, BoelaertM, LesaffreE (2013) Bayesian meta-analysis of diagnostic tests allowing for imperfect reference standards. Stat Med32, 5398–5413.
93.
BenamerTS, PattersonJ, GrossetDG, BooijJ, de BruinK, van RoyenE, SpeelmanJD, HorstinkMH, SipsHJ, DierckxRA, VersijptJ, DecooD, Van Der LindenC, HadleyDM, DoderM, LeesAJ, CostaDC, GacinovicS, OertelWH, PogarellO, HoeffkenH, JosephK, TatschK, SchwarzJ, RiesV (2000) Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: The [123I]-FP-CIT study group. Mov Disord15, 503–510.
94.
McKeithI, O’BrienJ, WalkerZ, TatschK, BooijJ, DarcourtJ, PadovaniA, GiubbiniR, BonuccelliU, VolterraniD, HolmesC, KempP, TabetN, MeyerI, ReiningerC (2007) Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: A phase III, multicentre study. Lancet Neurol6, 305–313.
95.
ItohN, AraiH, UrakamiK, IshiguroK, OhnoH, HampelH, BuergerK, WiltfangJ, OttoM, KretzschmarH, MoellerHJ, ImagawaM, KohnoH, NakashimaK, KuzuharaS, SasakiH, ImahoriK (2001) Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer’s disease. Ann Neurol50, 150–156.
